Related Tags >> Phase III Merck Eli Lilly Phase II

sepsis News

Most Popular sepsis Story

ALSO NOTED: CRO market hits $14B; Merck ends BioXell pact; and much more...

July 20, 2007 — 5:59am ET

> Merck has ended its collaboration with BioXell on its sepsis drug TREM-1. BioXell says it will seek another company with which to partner on the drug. Report > Shire Read more...

sepsis Press Releases

Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PC
SPECTRAL OBTAINS EXCLUSIVE CANADIAN DISTRIBUTION RIGHTS FOR TORAYMYXIN™
bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK

Latest Headlines

Lilly spins off sepsis drug into a biotech start-up
May 23, 2011
Eisai scraps blockbuster app after Ph3 sepsis drug trial derails
January 25, 2011
ALSO NOTED: CRO market hits $14B; Merck ends BioXell pact; and much more...
July 20, 2007
Press Release: AlphaRx Inc. Provides Positive Update On Indaflex
January 10, 2007
New trial for CytoFab as investors urge action
November 2, 2006
ALSO NOTED: Ariad selling shares; Indevus gains milestone; Barr closing on Pliva; and much more...
October 19, 2006
NIH group accuses Lilly of manipulating guidelines
October 18, 2006
Start-up pockets $39M, licenses new biologic
September 5, 2006
ALSO NOTED: XTL raises $28M; Wex to cut jobs; hedge fund resists Chiron acquisition;and much more...
March 19, 2006
Protherics shares soar on $338M licensing pact
December 7, 2005
Eisai plans pivotal trial of experimental sepsis therapy
August 28, 2005
ALSO NOTED: Able Labs files Ch. 11; Vertex wins fast track; Tamiflu works against avian flu; and much more...
July 18, 2005

Paid Research Reports

More Research Reports >>